Search...
LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-Driven Antibody Optimisation Programs
I'm PortAI, I can summarize articles.
LabGenius Therapeutics announced a second collaboration with Sanofi. This collaboration combines LabGenius' AI/ML-driven antibody design capabilities with Sanofi's expertise in the development of therapeutic NANOBODY molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA platform to optimise NANOBODY molecules for multiple new targets in the area of inflammation.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments